EGFR and head and neck squamous cell carcinoma: Consistent with the prevalence of EGFR protein overexpression and demonstrating its importance, EGFR- targeted antibody, cetuximab, is currently the only FDA- approved targeted therapy for HNSCC and has been shown to improve overall survival of patients [81, 82].